Market Tracker

12/06 4:48pm ET

MannKind Corp (NASDAQ:MNKD)

0.6431
Delayed Data
As of 4:00pm ET
 +0.0607 / +10.42%
Today’s Change
0.41
Today|||52-Week Range
2.24
-55.65%
Year-to-Date
Better Buy: MannKind Corp. vs. Novo Nordisk
8:10am / MotleyFool.com - Paid Partner Content
MannKind (MNKD): Strong Industry, Solid Earnings Estimate Revisions
Dec 01 / Zacks.com - Paid Partner Content
Biotech's Dumbest CEO Moves in 2016
Dec 05 / MotleyFool.com - Paid Partner Content
3 Biotech Investing Tips That Could Earn You Thousands
Nov 28 / MotleyFool.com - Paid Partner Content

Today’s Trading

Previous close0.58
Today’s open0.58
Day’s range0.56 - 0.66
Volume6,431,493
Average volume (3 months)3,820,291
Market cap$278.6M
Dividend yield--
Data as of 4:00pm ET, 12/06/2016

Growth & Valuation

Earnings growth (last year)-78.43%
Earnings growth (this year)+112.45%
Earnings growth (next 5 years)+26.80%
Revenue growth (last year)--
P/E ratioNM
Price/Sales--
Price/Book--

Competitors

 Today’s
change
Today’s
% change
PETXAratana Therapeutics...+0.36+4.75%
TRVNTrevena Inc+0.23+4.27%
CARACara Therapeutics In...+0.05+0.51%
ESPREsperion Therapeutic...-0.06-0.51%
Data as of 4:00pm ET, 12/06/2016

Financials

Next reporting dateMarch 20, 2017
EPS forecast (this quarter)-$0.04
Annual revenue (last year)$0.00
Annual profit (last year)-$368.4M
Net profit margin--

Profile

Sector
Health Technology
Industry
Biotechnology
CEO, CFO, Director, VP &
Head-Investor Relations
Matthew J. Pfeffer
Chief Medical Officer &
Vice President
Raymond W. Urbanski
Corporate headquarters
Valencia, California

Forecasts